HC Wainwright Has Negative Outlook for Korro Bio Q1 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Stock analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for Korro Bio in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($2.54) for the quarter, down from their previous forecast of ($2.45). HC Wainwright currently has a “Buy” rating and a $115.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

A number of other equities analysts have also weighed in on KRRO. Royal Bank of Canada reduced their price objective on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, March 19th. Oppenheimer assumed coverage on Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Korro Bio has a consensus rating of “Buy” and a consensus target price of $142.57.

Korro Bio Price Performance

NASDAQ KRRO opened at $24.03 on Monday. Korro Bio has a 1 year low of $18.50 and a 1 year high of $98.00. The company has a market capitalization of $225.62 million, a PE ratio of -2.56 and a beta of 2.13. The company has a fifty day moving average of $29.60 and a 200 day moving average of $41.23.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, beating the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million for the quarter.

Institutional Trading of Korro Bio

A number of institutional investors and hedge funds have recently made changes to their positions in KRRO. Quest Partners LLC lifted its position in shares of Korro Bio by 172.1% during the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after buying an additional 1,124 shares in the last quarter. Brown Brothers Harriman & Co. lifted its holdings in Korro Bio by 251.0% during the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock valued at $95,000 after purchasing an additional 2,041 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Korro Bio by 1,018.2% in the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock valued at $164,000 after purchasing an additional 4,470 shares during the period. MetLife Investment Management LLC grew its position in shares of Korro Bio by 129.0% in the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock valued at $122,000 after purchasing an additional 2,050 shares during the period. Finally, State Street Corp increased its stake in shares of Korro Bio by 18.9% during the third quarter. State Street Corp now owns 118,765 shares of the company’s stock worth $3,969,000 after purchasing an additional 18,877 shares in the last quarter. 13.18% of the stock is currently owned by hedge funds and other institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).